Analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to announce sales of $4.25 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $7.00 million. Adaptimmune Therapeutics posted sales of $9.04 million in the same quarter last year, which suggests a negative year over year growth rate of 53%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Adaptimmune Therapeutics will report full year sales of $15.17 million for the current financial year, with estimates ranging from $4.50 million to $21.00 million. For the next year, analysts forecast that the firm will post sales of $17.75 million, with estimates ranging from $1.00 million to $36.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%.
NASDAQ ADAP opened at $4.02 on Friday. Adaptimmune Therapeutics has a 1-year low of $3.20 and a 1-year high of $14.54. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55. The firm has a market capitalization of $413.53 million, a P/E ratio of -4.19 and a beta of 1.56. The stock has a fifty day moving average of $3.69.
A number of large investors have recently modified their holdings of the stock. Baillie Gifford & Co. boosted its holdings in Adaptimmune Therapeutics by 3.8% in the first quarter. Baillie Gifford & Co. now owns 3,839,190 shares of the biotechnology company’s stock worth $16,508,000 after purchasing an additional 139,669 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in Adaptimmune Therapeutics by 102.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,350,655 shares of the biotechnology company’s stock worth $7,766,000 after purchasing an additional 684,062 shares in the last quarter. BlackRock Inc. boosted its holdings in Adaptimmune Therapeutics by 10.4% in the fourth quarter. BlackRock Inc. now owns 856,415 shares of the biotechnology company’s stock worth $4,924,000 after purchasing an additional 81,010 shares in the last quarter. Foresite Capital Management II LLC boosted its holdings in Adaptimmune Therapeutics by 40.0% in the fourth quarter. Foresite Capital Management II LLC now owns 700,000 shares of the biotechnology company’s stock worth $4,025,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Rathbone Brothers plc boosted its holdings in Adaptimmune Therapeutics by 27.9% in the first quarter. Rathbone Brothers plc now owns 285,722 shares of the biotechnology company’s stock worth $1,229,000 after purchasing an additional 62,292 shares in the last quarter. Hedge funds and other institutional investors own 66.30% of the company’s stock.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Read More: Why are percentage decliners important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.